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(The genetics of) 
breast cancer
Big news recently was Angeline Jolie’s 
‘medical choice’ to have a preventive double 
mastectomy.[1] Co-incidentally the SAMJ had 
received articles dealing with breast cancer, 
including its genetic diagnosis, and several 
relating to maternal and neonatal health. We 
opted to make this August issue a Women’s 
Month edition.
The incidence of breast cancer in sub-
Saharan Africa (SSA) is reportedly low at 
20  cases per 100 000 population, compared 
with 90/100  000 in the West. However, this 
undoubtedly reflects under-diagnosis, espe-
cially since breast cancer is closing in on cervical 
cancer as the most common malignancy 
affecting women, and the incidence rates 
appear to be rising.
In developed countries, breast cancer is a 
disease of older women. However, in SSA, 
more than 50% of patients are premenopausal. 
In developing and resource-poor countries 
women present very late – in the Eritrean study 
in this issue,[2] over 70% of patients sought 
consultation more than 1 year after noticing 
symptoms. Not surprisingly 1 in 5 of such 
women had advanced stage disease and distant 
organ metastasis. Many women had resorted 
to ‘traditional’ therapy (e.g. herbal medicine, 
holy water, soil), which further exacerbated 
their poor outcome and prognosis.
The situation is happier in our own country 
– as our vivid guest editorial notes. We are 
fortunate to have available modern diagnostic 
technology, including sophisticated genetic 
testing.[3]
An editorial from Urban[4] contains advice 
for the generalist on how to avoid ordering 
genetic tests that, without appropriate genetic 
counselling[5] of patient and family members, 
would prove frivolous – ‘recreational’ is his 
term – and even potentially harmful.
Mother and child health - 
outlook for South Africa
South Africa (SA) is a long way off from 
meeting Millennium Development Goals 4 
and 5 by 2015. However, an editorial from 
Burton[6] offers a glimmer of hope, and one 
from Lloyd and de Witt,[7] shows – based on 
their experience at the Steve Biko Academic 
Hospital – how simple measures undertaken 
by midwives, could improve outcomes. 
On a related note, Schoon,[8] writing of the 
experience in the Free State, where maternal 
mortality rates are among the highest in 
South Africa, provides a valuable insight: 
by the simple expedient of arranging that 
there be dedicated inter-facility transport for 
pregnant mums in trouble, maternal mortality 
was dramatically reduced (see figure above). 
HIV and maternal 
mortality
The HIV pandemic has become increasingly 
feminised, with HIV prevalence among ante-
natal clinic attendees at 30%, (even higher in 
the Pietermaritzburg area, at 42%). HIV/AIDS 
is thus the major cause of maternal deaths. 
Given the scarcity of intensive care unit (ICU) 
facilities in our public sector environment, 
it seems reasonable to ask, as Ngene et  al. [9] 
do, whether HIV-positive pregnant women 
should receive ICU care or not. In a prospective 
study, they determined the maternal and fetal 
outcomes of HIV-positive and -negative 
patients, whether pregnant or postpartum, and 
constituting almost 10% of all admissions to 
ICUs. The chief pre-ICU admission diagnosis 
was pre-eclampsia/eclampsia syndrome, 
more common among HIV-negative than 
HIV-positive patients. Among HIV-positive 
patients, pneumonia, reflecting immune 
suppression, was the most common diagnosis. 
All maternal and fetal outcomes showed a 
worse trend with HIV-positive v. HIV-
negative patients. These findings are likely to 
favour HIV-negative pregnant women, with 
their better-expected outcomes, over their 
HIV-positive counterparts for admission to 
ICU. Larger studies are urgently needed to 
investigate these trends more completely. The 
authors believe that, until such studies are 
done, HIV sero-status should not be used as 
an isolated determinant of admission to ICU. 
High-risk patients, 
expertly guided, can 
benefit from PrEPs
When it comes to treatment, very few HIV 
clinicians dispute the overall efficacy of 
increasing the CD4+ count threshold from 
350 to 500 in initiating antiretroviral therapy 
(ART) (a probability from 1 April 2014), or 
the value of fixed-dose combinations. The 
same goes for prevention (e.g. circumcision, 
vaginal-based microbicides best applied 
before and after predictable sex, or condoms/
femidoms). However, when it comes to 
treatment-as-prevention, ranging from 
ART at diagnosis of HIV to pre-exposure 
prophylactics (PrEPs), the debate heats up, 
especially with the latter. The PrEP issue was 
thoroughly vented at the June/July national 
AIDS conference in Durban. Izindaba 
reports[10] from experts at the coalface on just 
how, where and for whom it makes the most 
sense, and most critically, which high-risk 
groups might be most adherent. Much of it 
is based on pragmatic common sense, e.g. 
(generally) why would a discordant couple 
use PrEPs when antiretrovirals with condoms 
pretty much do the trick? Field studies show 
appalling adherence to PrEPs, but in the 
real world, sex workers are already showing 
95% adherence to ART (and they are hyper-
aware of the risks of their trade). Used highly 
selectively, it is a handy addition to our self-
defence weaponry.
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Inter-facility vehicles dispatched v. maternal mortality (from Schoon, in this issue).[8]
